Phase 3 N=156 Reducing Emergency Diabetes Care for Older African Americans
Diabetes Mellitus
Primary: Number of Incident Diabetes-related ED Visits and/or Hospitalizations — .88; 1.29 Incidence rate ratio — p=.12
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=65 PREVENT Tool Study: Late Effects Clinic
Cardiovascular Disease · Childhood Obesity
Primary: Mean Change in Minutes of Moderate Physical Activity Per Week (From Self Report) Survey — 43.3; 16.8 minutes/week
N/A N=35,953 Cancer Prevention Clinical Decision Support
Cancer Prevention
Primary: Composite Cancer Screening Tests up to Date — 3087; 2590; 3866 Participants — p=.025
N/A N=417 Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?
Health Risk Appraisal · Heart Disease · Prevention
Primary: Enrollment in Prevention Services — 91; 56 participants — p=<.0001
Phase 2 N=267 Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
HIV Prevention · HIV Infections
Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05
N/A N=1,377 PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare
PrEP Precriptions for Reproductive Aged Women
Primary: PrEP Prescriptions — 11; 0 Participants
N/A N=5,117 Periodontal Disease Prevention Study
Periodontitis
Primary: Percentage of Participants With Tooth Loss Over 16 Year Period — 16.4; 13.8; 22.1; 16.9 percentage of participants
N/A N=360 Bridging the Gap From Postpartum to Primary Care
Hypertension · Hypertension in Pregnancy · Diabetes Mellitus
Primary: Rate of Primary Care Provider Visit Attendance — 38; 72 Participants — p=<0.001
N/A N=799 Positive Health Check Evaluation Trial
Human Immunodeficiency Virus (HIV) Positive
Primary: Number of Participants With Viral Load Suppression — 210; 213 Participants — p=0.220
N/A N=322 The Pitt Retiree Study: A Diabetes Prevention Program for Medicare Eligible Older Adults
Obesity · Cardiovascular Risk Factor · Eating Behavior
Primary: Change in Bodyweight — -7.4; -6.1 percent weight change — p=0.01
N/A N=125 BETTER HEALTH: Durham
Cancer and Chronic Disease Prevention
Primary: Composite Outcome Measure: Mean Percentage of CDPS Actions at Baseline That Are Subsequently Met at Follow-up — 64.5; 42.1 percent of actions
N/A N=401 Randomized Controlled Trial of Group Prevention Coaching
Cardiovascular Disease
Primary: Risk of Fatal Coronary Event or Non-fatal MI — 27.0; 26.3 percent risk of major cv event in 10 yrs — p=0.50
N/A N=37 Personal Resilience Empowerment Program Study
Lung Cancer · Cholangiocarcinoma · Pancreatic Cancer
Primary: Change in Quality of Life Post Intervention (Coaching Sessions) - Sleep — -1.06; -0.80 scores on a scale
N/A N=90 Patients Engaged in Prevention: Enhancing Outreach to Increase Patient Engagement in Diabetes Prevention
Preventive Health Services · Health Communication
Primary: Acceptance of Health Message — 5.5; 5.4 units on a scale — p=0.18
N/A N=857 US PRECISION Implementation Study
Asthma
Primary: Percentage Endorsement of Responses by Site HCPs for Each Categorical Item on the Post-study Survey Relating to Overall Ease of Implementing AIRQ Into Clinical Practice…
N/A N=62 Evaluating a Type 2 Diabetes Prevention Program
Type 2 Diabetes · PreDiabetes
Primary: Body Mass Index (BMI) - Post-Test — 30.3; 28.8 kg/m2
N/A N=483 Presessions for the National Diabetes Prevention Program
Prediabetic State · Obesity · Gestational Diabetes
Primary: Weight Loss — 3.1; 2.8 % of weight loss
N/A N=5,269 Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Myocardial Ischemia · Rheumatic Diseases
Primary: Proportion of Days Covered (PDC) — 82.6; 75.6; 78.4; 73.3 percentage of days covered
N/A N=138 Previvors Recharge: A Resilience Program for Cancer Previvors
Hereditary Cancer · Mental Health Issue
Primary: Connor Davidson Resilience Scale (CDRISC) — 22.59; 23.53 score on a scale — p=.029
Phase 3 N=2,060 Preventing Caries in Preschoolers: Testing a Unique Service Delivery Model in American Indian Head Start Programs
Fluoride Varnish and Oral Health Promotion · Usual Care
Primary: Evaluation of Decayed, Missing, and Filled Tooth Surfaces (Dmfs) at Baseline — 19.9; 22.8 dmfs
N/A N=51 Healthy Living Partnerships to Prevent Diabetes in Veterans Pilot Study
Pre-diabetes · Obesity
Primary: Recruitment of Study Participants — 58; 51 Participants
N/A N=123 Technology-Based Prevention for Adolescents in Primary Care
Substance Use
Primary: Enrollment and Recruitment Rate — 61; 62 Participants
N/A N=637 The Oakland Men's Health Disparities Study
Behavior · Cardiovascular Risk Factor · Influenza
Primary: Average Take-up of Preventive Services (Post-consultation) — 0.52; .71 score on a scale
N/A N=318 Pre-exposure Prophylaxis (PrEP) at Home
HIV/AIDS
Primary: Number of Participants Achieving Appropriate Levels of Tenofovir-diphosphate (TFV-DP) at 6-month Follow-up — 78; 39 Participants
Phase 1 N=183 Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening
Colorectal Carcinoma
Primary: Change in Screening Metrics — 42; 8; 37; 13 Participants
N/A N=459 SUPPORT FOR FRAIL ELDERLY PERSONS - From Prevention to Palliation
Frail Elderly Persons
Primary: Dependence in Two or More Activities of Daily Living (ADL) — 35; 26; 44 participants — p=<0.05
Phase 3 N=39,876 Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer
Cardiovascular Diseases · Cerebrovascular Disorders · Coronary Disease
Primary: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) — 245…
Phase 4 N=301 A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
HIV Prevention
Primary: Number of Participants With a Grade 2 or Higher Adverse Event by Cohort — 230; 0 Participants
Phase 2 N=130 COVID-19 PrEP HCW HCQ Study
COVID-19
Primary: Change From Baseline in the Number of Participants With Seroconversion to SARS-CoV-2 at 1 Month — 4; 2 Participants
N/A N=18,882 UH3 Pragmatic Suicide Prevention Trial
Depression · Suicidal Ideation
Primary: Time to Fatal or Non-fatal Suicide Attempt or Self-Harm — 548; 548; 548 Days of follow-up time — p=0.61